^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MCI-030

i
Other names: MCI-030, ANC 061
Associations
Trials
Company:
ADT Pharma, ChemomAb
Drug class:
β-catenin inhibitor, PDE10 inhibitor
Associations
Trials
2years
Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer. (PubMed, J Ovarian Res)
Using small molecule inhibitors, Pf-2545920 and a novel NSAID-derived PDE10A inhibitor, MCI-030, we show that PDE10A inhibition leads to decreased ovarian cancer cell growth and induces cell cycle arrest and apoptosis...We also demonstrate that PDE10A inhibition leads to decreased Wnt-induced β-catenin nuclear translocation, as well as decreased EGF-mediated activation of RAS/MAPK and AKT pathways in ovarian cancer cells. These findings implicate PDE10A as novel target for ovarian cancer chemoprevention and treatment.
Journal
|
EGF (Epidermal growth factor) • LINC00473 (Long Intergenic Non-Protein Coding RNA 473)
|
MCI-030